Vorbipiprant

DB16111InvestigationalSmall molecule

CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in Dmard-naïve Patients With Early Rheumatoid Arthritis).

Mechanism: Pharmacologically active on Prostaglandin E2 receptor EP4 subtype
Curator reviewed
Formula / weight: C₂₆H₂₇F₃N₂O₃ · 472.508 g/mol (avg)
Code names: CR-6086

Resolves to

Compound

UNIITNK4EB6VB5CAS1417742-86-9ChEMBLCHEMBL3920982

Structure

InChIKeyCADWTPLFEZSAHM-UHFFFAOYSA-NSMILESOC(=O)C1=CC=C(C=C1)C1(CC1)NC(=O)C1CC2(CC2)CCN1CC1=CC=C(C=C1)C(F)(F)F

Targets

P35408PTGER4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vorbipiprant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account